Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-03-21
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines and, with Vertex, commercializes CASGEVY while advancing in vivo editing, cell therapy, siRNA, and regenerative medicine programs.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved proof, but scale needs more than one win
The setup is attractive because one approved therapy plus a large balance sheet gives real option value on multiple 2026-2027 catalysts. The stock works best if commercial throughput improves and at least one follow-on franchise becomes clearly real, not just scientifically interesting.

Analysis

Thesis
CRISPR Therapeutics has already crossed the hardest credibility gap with the first approved CRISPR therapy; if 2026-2027 data convert that proof into one additional real franchise in in vivo editing, autoimmune cell therapy, or siRNA, the stock can rerate meaningfully from a cash-cushioned EV, though throughput and regulatory gating keep this in the 2-5x class rather than true hypergrowth.
Last Economy Alignment
AI should lower biological design and process-learning costs, helping CRISPR reuse editing, delivery, and manufacturing know-how across programs. But value capture is still constrained by regulators, treatment-center logistics, and partner-controlled commercial surfaces rather than pure software-like scaling.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.7x (from 5 most recent analyses)
Reasoning
Today the market gives CRISPR partial credit for approved-product proof, a broad pipeline, and a large balance sheet, but not for repeatable multi-asset commercialization. If CASGEVY throughput improves and one or two follow-on programs become commercially credible, investors can re-rate the company from a single-asset gene-editing story into a platform builder. I do not underwrite a moonshot because biology, regulation, and care-delivery friction still slow scaling.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The central risk is not software-style commoditization; it is that CRISPR fails to prove repeatable human efficacy and scalable delivery beyond CASGEVY. The biggest practical gates are CASGEVY throughput, pediatric expansion, and whether CTX310, CTX340, zugo-cel, or CTX611 mature into assets that can justify platform value rather than isolated option value.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.36
They already control real gene-editing know-how, some manufacturing capability, and one approved therapy, so better AI-driven biology should help them design and improve more medicines. The catch is that regulators, treatment-center bottlenecks, and partner-controlled commercialization still decide how much of that value they actually keep.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$74.33
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case